News >

Apalutamide Approval Paves Way for Further Advances in Nonmetastatic CRPC

Caroline Seymour
Published: Wednesday, Mar 07, 2018

Alan H. Bryce, MD

Alan H. Bryce, MD
The space of nonmetastatic castration-resistant prostate cancer (CRPC) is beginning to evolve with recent advances highlighted by the FDA-approval of apalutamide (Erleada).

The FDA based its decision on findings from the phase III SPARTAN trial, in which the median metastasis-free survival (MFS) was 40.5 months in the apalutamide arm versus 16.2 months in the placebo arm (HR, 0.28; 95% CI, 0.23-0.35; P <.0001).1

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication